No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.0x · 10Y median 5.1x · 15th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:53:09.703Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T17:53:09.703Z. Latest historical point 2026-05-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T17:53:09.703Z. Latest historical point 2026-05-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:53:09.703Z. Latest historical point 2026-05-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:53:09.703Z. Latest historical point 2026-05-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Scilex Holding Company (SCLX) stock was $3.84 as of Oct 6, 2026, 1:46 PM EDT, up 0.52% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -75.6% · 3-year avg -58.1%/yr · 5-year avg -59.5%/yr
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles.
Drug Manufacturers - General · Palo Alto, CA
Next Earnings Date
Dec 2, 2026
57 days away
EPS Estimate
-0.08
Revenue Est.
$17.00M
Last Quarter Results
EPS
$-1.17
vs Estimate
$-0.47
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SCLX | $32.61M | $3.84 | +0.52% | -75.63% | -59.50% | N/A | N/A |
| 2ALGS | $32.92M | $5.32 | -1.48% | -46.22% | -57.15% | N/A | vs SCLX |
| 3BEAT | $33.11M | $0.60 | -8.82% | -66.28% | N/A | N/A | vs SCLX |
| 4RMTI | $31.97M | $8.10 | -1.58% | -32.41% | -33.38% | -36.28% | vs SCLX |
| 5EUDA | $33.63M | $18.01 | +4.12% | -61.04% | N/A | N/A | vs SCLX |
| 6NSYS | $31.47M | $11.26 | +1.90% | +22.66% | -1.64% | +11.22% | vs SCLX |
forward FY estimate
N/A
$7.64M
vs Estimate
$16.00M
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$3.84
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Quarter ending Dec 2026 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Quarter ending Mar 2027 | $0.11 | $0.11 | $0.11 | 1 |
| Quarter ending Jun 2027 | $0.15 | $0.15 | $0.15 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.55 | $-0.55 | $-0.55 | 1 |
| FY 2027 | $0.45 | $0.45 | $0.45 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $17.00M | $17.00M | $17.00M | 1 |
| Quarter ending Dec 2026 | $18.00M | $18.00M | $18.00M | 1 |
| Quarter ending Mar 2027 | $45.35M | $45.35M | $45.35M | 1 |
| Quarter ending Jun 2027 | $47.24M | $47.24M | $47.24M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $66.00M | $66.00M | $66.00M | 1 |
| FY 2027 | $188.97M | $188.97M | $188.97M | 1 |
